Reduced-frequency bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV: a single-centre randomised phase 2 pilot trial in Spain
Open Access
- 23 August 2026
- journal article
- Published by Elsevier in eClinicalMedicine
- Vol. 99, 104158
Abstract
No abstract availableKeywords
Funding Information
- Institut d’Investigacions Biomèdiques August Pi i Sunyer, Universitat de Barcelona (II040141)
- Institut d'Investigacions Biomèdiques August Pi i Sunyer
- Instituto de Salud Carlos III (PI20/00869)
- Instituto de Salud Carlos III (PI20/00676)
- Instituto de Salud Carlos III (PI24/00816)
This publication has 31 references indexed in Scilit:
- Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society–USA PanelJAMA, 2025
- Plasma, intracellular and lymph node antiretroviral concentrations and HIV DNA change during primary HIV infection: Results from the INACTION P25 studyInternational Journal of Antimicrobial Agents, 2024
- Preferences of People Living with HIV for Long-Acting Antiretroviral Treatment in Germany: Evidence from a Discrete Choice ExperimentThe Patient - Patient-Centered Outcomes Research, 2023
- A partner protection package for HIV cure-related trials involving analytical treatment interruptionsThe Lancet Infectious Diseases, 2023
- Validity of the EQ–5D–5L and reference norms for the Spanish populationQuality of Life Research, 2018
- A Review of Long-Term Toxicity of Antiretroviral Treatment Regimens and Implications for an Aging PopulationInfectious Diseases and Therapy, 2018
- Establishment of intracellular tenofovir-diphosphate as the key determinant for in vitro-in vivo translation of antiviral efficacyAntiviral Research, 2018
- UPLC–MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasmaJournal of Pharmaceutical and Biomedical Analysis, 2017
- Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trialThe Lancet, 2014
- Exploring Concentration Response in HIV Pre-Exposure Prophylaxis to Optimize Clinical Care and Trial DesignCell, 2013